%0 Journal Article
%T Circulating tumor DNA evaluated by Next-Generation Sequencing is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer
%A Catherine Julie
%A Coraline Dumenil
%A Etienne Giroux Leprieur
%A Guillaume Herbretau
%A H¨¦l¨¨ne Blons
%A Jean-Fran£¿ois Emile
%A Jennifer Dumoulin
%A Julie Tisserand
%A Sylvie Labrune
%A Thierry Chinet
%A Violaine Giraud
%J Archive of "Oncoimmunology".
%D 2018
%R 10.1080/2162402X.2018.1424675
%K nivolumab
%K circulating tumor DNA
%K anti-PD1
%K immune checkpoint inhibitor
%K tumor response
%K clinical benefit
%K somatic mutation
%K non-small cell lung cancer
%K next-generation sequencing
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927532/